Articles related to DEVICE/DRUG APPROVALS

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.

The approval of Zilbrysq marks a significant advancement in the treatment landscape for generalized myasthenia gravis. With its unique mechanism of action and self-administration, it offers a promising new option for patients.

With more than 5,000 patients studied in clinical trials, Exxua has demonstrated effectiveness for relieving depressive symptoms with an acceptable side effect profile.

Stay informed about the latest research on factors influencing COVID-19 outcomes. Learn more about how these findings could influence your approach to patient care.

The FDA’s recent approval of Pombiliti + Opfolda just expanded treatment options for the rare inherited lysosomal disorder.

Discover how the FDA-approved Invitae’s Common Hereditary Cancers Panel can enhance your approach to early cancer detection and personalized treatment planning.